Despite the limited responses to nivolumab seen in the primary tumor, our study provides important hypothesis-generating insights into the biology underlying response and resistance to anti-PD-1 monotherapy, which is crucial to better understand the synergistic effects of combination drug therapies in treating ccRCC. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.